Comparison of levofloxacin based versus clarithromycin based triple regimen therapy for in the eradication of helicobacter pylori
Abstract
Background: Helicobacter pylori is a globally prevalent gastric pathogen implicated in chronic gastritis, peptic ulcer disease, and gastric malignancies. Rising resistance to commonly used antibiotics, particularly clarithromycin, has led to declining eradication success rates with conventional therapies. Levofloxacin, a fluoroquinolone antibiotic, has emerged as a potential alternative in triple therapy regimens. Evaluating the comparative effectiveness of these treatment options in different populations is essential to guide empirical clinical practice and adapt to regional antibiotic resistance patterns.
Objective: To compare the success of levofloxacin-based versus clarithromycin-based triple regimen therapy in the eradication of Helicobacter pylori infection.
Methods: This randomized controlled trial was conducted at the Department of Gastroenterology, Sheikh Zayed Medical Complex, Lahore, from April 2 to October 2, 2020. A total of 120 patients, aged 16 to 75 years and diagnosed with H. pylori via ^13C urea breath test, were enrolled and randomly allocated into two equal groups. Group A received omeprazole 40 mg, amoxicillin 1 g, and levofloxacin 250 mg twice daily for 14 days. Group B received omeprazole 40 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for the same duration. After 28 days of treatment completion, H. pylori status was reassessed using the ^13C urea breath test. Eradication success was defined by a negative result.
Results: The mean age of…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 120 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.